Rakovina Therapeutics Inc. Receives European and Canadian Patents on kt-2000 series PARP-inhibitors Lead candidates from Rakovina Therapeutics' kt-2000 series exhibit potency comparable to FDA-approved PARP-inhibitors and potent anti-cancer
Beyond Medical Manufactures N95 Medical Face Masks as Third Wave of COVID-19 Surges Micron Technologies has submitted its N95 Model 8800 face masks to NIOSH and is confident it will obtain NIOSH certification...
Rakovina Therapeutics Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board Dr. Cherrington is an accomplished life science executive with a record of success bringing drug candidates through to commercialization...
